Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05875168 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT05875168: Recruiting Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Daiichi Sankyo.
NCT05875168 is a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 540 participants, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (184% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05875168, a Phase 1 study of Advanced Solid Tumor and Metastatic Solid Tumor, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
Conditions Studied
Interventions
- DRUG DS-3939a
Study Locations (20)
Other
- UZ Leuven - Leuven
- McGill University Health Center - Montreal
- Princess Margaret Cancer Center - Toronto
- Beijing Cancer Hospital - Beijing
- Shandong Cancer Hospital - Jinan
- The Second Peoples Hospital of Neijiang - Neijiang
- Shanghai East Hospital - Shanghai
- Centre Léon Bérard - Lyon
- Assistance Publique- de Marseille - Marseille
- Chu Strasbourg - Strasbourg
- Institut Claudius Regaud - Toulouse
- Institut Gustave Roussy - Villejuif
- National Cancer Center Hospital - Chūōku
- Kansai Medical University Hospital - Hirakata-shi
Florida
- Florida Cancer Specialists - Sarasota
Oregon
- Oregon Health & Science University - Portland
Rhode Island
- Rhode Island Hospital - Providence
Texas
- University of Texas M.D. Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Wisconsin
- The Medical College of Wisconsin, INC - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2023-08-18 |
| Est. Completion | 2027-02-15 |
| Phase | Phase 1 |
What NCT05875168 shows while recruiting
NCT05875168 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, above the 190-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (184% higher).
The record links to 2 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which DS-3939a is the first listed.
NCT05875168 names 20 study sites across 7 states, led by Other, Florida, Oregon.
Frequently Asked Questions
What is clinical trial NCT05875168 about?
NCT05875168 is a clinical study titled "First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors". This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
What is the current status of trial NCT05875168?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 540 participants. The study started on 2023-08-18. Estimated completion is 2027-02-15.
What conditions does trial NCT05875168 study?
This clinical trial studies the following conditions: Advanced Solid Tumor, Metastatic Solid Tumor.
What interventions are being tested in trial NCT05875168?
The interventions under investigation include: DS-3939a (DRUG).
Who is sponsoring clinical trial NCT05875168?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05875168 being conducted?
This trial has 20 study locations across Florida, Oregon, Rhode Island, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05875168's enrollment target sits among peer trials
540 8th of 189 higher than 182 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI